This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Fungal Infections in Lung Transplantation
Current Transplantation Reports Open Access 09 May 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265–273.
Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471–5489.
Girmenia C, Barosi G, Piciocchi A, Arcese W, Aversa F, Bacigalupo A et al. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 2014; 20: 1080–1088.
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335–347.
Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ . Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56: 5503–5510.
Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG . Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27: 825–834.
Cho E, Chan H, Nguyen HM, Shayani S, Nakamura R, Pon D . Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant. Pharmacotherapy 2015; 35: 578–585.
Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect 2014; 20: O952–O959.
Peksa GD, Schultz K, Fung HC . Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract 2015; 21: 409–415.
Girmenia C, Barosi G, Aversa F, Bacigalupo A, Barbui T, Baronciani D et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 2009; 49: 1226–1236.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821.
Greco R, Oliveira G, Stanghellini MT, Vago L, Bondanza A, Peccatori J et al. Improving the safety of cell therapy with the TK-suicide gene. Front Pharmacol 2015; 6: 95.
Cornely OA, Ullmann AJ . Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 2011; 89: 351–352.
Dolton MJ, Ray JE, Marriott D, McLachlan AJ . Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56: 2806–2813.
Krishna G, Ma L, Martinho M, O'Mara E . Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012; 56: 4196–4201.
Acknowledgements
This work was supported by the Italian Ministry of Health (RF-2011-02351998). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author contributions
RG, MCB and FC designed the study and analyzed the data. RG, MCB, MTLS, FG, MM, CM, AF, CO, SP, PS, SM, AA, MC, LV, CC, MB, JP and FC contributed to patient clinical care and data collection. RG, MCB and FC wrote the manuscript. All authors have approved the final version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Greco, R., Barbanti, M., Lupo Stranghellini, M. et al. Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 51, 1022–1024 (2016). https://doi.org/10.1038/bmt.2016.112
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.112
This article is cited by
-
Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir
Bone Marrow Transplantation (2023)
-
Fungal Infections in Lung Transplantation
Current Transplantation Reports (2022)
-
Effect of posaconazole on the concentration of intravenous and oral cyclosporine in patients undergoing hematopoietic stem cell transplantation
European Journal of Clinical Pharmacology (2022)